Levetiracetam-induced parkinsonism in a Huntington disease patient.
The authors present a man with Huntington disease who was treated with levetiracetam (Keppra) in an effort to reduce chorea. Chorea was markedly reduced, but the patient developed parkinsonism and lethargy after 6 weeks of treatment. Symptoms consisted of resting tremor, rigidity, increased dystonia, and gait difficulty. Side effects from levetiracetam resolved completely within 7 days of levetiracetam discontinuation, and chorea returned to baseline.
Zesiewicz
Theresa A
TA
Parkinson's Disease and Movement Disorders Center, NPF Centers of Experience, Department of Neurology, University of South Florida Tampa, Florida 33612, USA. tzesiewi@hsc.usf.edu
Sanchez-Ramos
Juan
J
Sullivan
Kelly L
KL
Hauser
Robert A
RA
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003704:Dementia / Q000188:drug therapy / Q000209:etiology; D020233:Gait Disorders, Neurologic / Q000139:chemically induced; D006801:Humans; D006816:Huntington Disease / Q000150:complications* / Q000188:drug therapy; D000077287:Levetiracetam; D008297:Male; D008875:Middle Aged; D009127:Muscle Rigidity / Q000139:chemically induced; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D010302:Parkinson Disease, Secondary / Q000139:chemically induced*; D010889:Piracetam / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014202:Tremor / Q000139:chemically induced
D014150:Antipsychotic Agents; D018697:Nootropic Agents; D000077287:Levetiracetam; D010889:Piracetam